Autres langues Sanofi Euronext Paris

Actions

SANNV

FR001400M6Z3

Temps réel Euronext Paris Autres places de cotation 11:50:21 07/05/2024			Varia. 5j.	Varia. 1 janv.
91,2 ^EUR	-.--%		-.--%	-.--%

17:11	CAC40 : consolide en solo, 'spread' OAT/Bund se creuse à 81Pb	CF
16:32	Euroapi : échoue à rassurer malgré les 200 millions d'euros annoncés par Sanofi	AO

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CAC40 : consolide en solo, 'spread' OAT/Bund se creuse à 81Pb	17:11
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	15:18
Sanofi - Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM	14:31
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data	14:13
Top Premarket Gainers	13:55
Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment	12:55
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study	11:03
CAC40 : sous les 7600 pts, freiné par le secteur auto	10:58
Vigil Neuroscience Receives $40 Million Investment From Sanofi	09:41
The same old winners	09:00
Borsa di Italia: I soliti vincitori	08:00
Bolsa de Madrid: Los mismos ganadores de siempre	08:00
Sanofi : publication positive pour Dupixent dans le NEJM	07:48
Sanofi Partakes in Formation Bio's $372 Million Fundraising	06:56
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM	26/06
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine	26/06
FDA approves Verona Pharma's therapy for 'smoker's lungs'	26/06
Sanofi-backed Drug Developer Formation Bio Raises $372 Million	26/06
Sanofi-backed Formation Bio raises $372 million in late-stage funding round	26/06
Euroapi : mise à jour des perspectives 2024	26/06